Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex H Chang

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
JAMA Oncology|April 17, 2025
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical TrialMingming Zhang, Shan Fu, Jingjing Feng, et al.
Leukemia|May 22, 2019
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemiaJing Pan, Qing Niu, Biping Deng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2023
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ TrialJieyun Xia, Hujun Li, Zhiling Yan, et al.
The New England Journal of Medicine|April 24, 2024
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD ProphylaxisYongxian Hu, Mingming Zhang, Tingting Yang, et al.
The Lancet. Haematology|April 14, 2025
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trialJieyun Xia, Qian Sun, Dian Zhou, et al.
Molecular Oncology|February 22, 2025
Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancerMarina N Sharifi, Eric Feng, Nicholas R Rydzewski, et al.
Journal of Hematology & Oncology|May 6, 2020
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective studyHouli Zhao, Jieping Wei, Guoqing Wei, et al.
American Journal of Hematology|May 14, 2026
Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-UpHouli Zhao, Zhouning Lin, Haiqiong Zheng, et al.
The New England Journal of Medicine|January 14, 2026
CD19 CAR T-Cell Therapy for Autoimmune Hemolytic AnemiaRuonan Li, Hong Pan, Lele Zhang, et al.
Cancer Discovery|April 1, 2025
High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical OutcomesMarina N Sharifi, Jamie M Sperger, Amy K Taylor, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
JAMA Oncology|April 17, 2025
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical TrialMingming Zhang, Shan Fu, Jingjing Feng, et al.
Leukemia|May 22, 2019
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemiaJing Pan, Qing Niu, Biping Deng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2023
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ TrialJieyun Xia, Hujun Li, Zhiling Yan, et al.
The New England Journal of Medicine|April 24, 2024
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD ProphylaxisYongxian Hu, Mingming Zhang, Tingting Yang, et al.
The Lancet. Haematology|April 14, 2025
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trialJieyun Xia, Qian Sun, Dian Zhou, et al.
Molecular Oncology|February 22, 2025
Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancerMarina N Sharifi, Eric Feng, Nicholas R Rydzewski, et al.
Journal of Hematology & Oncology|May 6, 2020
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective studyHouli Zhao, Jieping Wei, Guoqing Wei, et al.
American Journal of Hematology|May 14, 2026
Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-UpHouli Zhao, Zhouning Lin, Haiqiong Zheng, et al.
The New England Journal of Medicine|January 14, 2026
CD19 CAR T-Cell Therapy for Autoimmune Hemolytic AnemiaRuonan Li, Hong Pan, Lele Zhang, et al.
Cancer Discovery|April 1, 2025
High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical OutcomesMarina N Sharifi, Jamie M Sperger, Amy K Taylor, et al.
Pageof 8